# A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus

> **NCT04515849** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 248 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus
- Chronic Kidney Diseases

## Interventions

- **DRUG:** Cotadutide 100 micrograms
- **DRUG:** Cotadutide 300 micrograms
- **DRUG:** Cotadutide 600 micrograms
- **DRUG:** Semaglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04515849
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-31
- **Primary completion:** 2022-03-08
- **Final completion:** 2022-03-08
- **Target enrollment:** 248 (ACTUAL)
- **Last updated:** 2025-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04515849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04515849, "A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04515849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*